Medtronic announces positive data adaptive deep brain stimulation trial

Medtronic has released preliminary findings from its study on the adaptive deep brain stimulation (aDBS) device, Percept PC neurostimulator, aimed at patients with Parkinson’s disease. The ADAPT-PD trial (NCT04547712) seeks to demonstrate the safety and effectiveness of aDBS, with data intended to support global regulatory filings.

The Percept PC DBS system, initially approved by the FDA for continuous DBS in 2020, treats Parkinson’s motor symptoms like tremors and rigidity. Unlike continuous stimulation, aDBS delivers personalized stimulation based on the patient's brain state, improving symptom control.

The study published in *npj Parkinson’s Disease* involved 68 participants, with the primary endpoint comparing aDBS to standard continuous DBS for effective "On" time without troublesome dyskinesias. Local field potential signals for aDBS programming were found in 84% of patients. The global neuromodulation market is projected to grow from $6.06 billion in 2023 to over $8.9 billion by 2027, with deep brain stimulation devices expected to constitute a significant portion.